As innovations in dental implant technology and equipment continue to advance and doctors refine their techniques, the future holds even more remarkable breakthroughs in this field of dentistry

CLEARWATER, Fla. (PRWEB)
June 27, 2023

Typically, tooth loss signifies the culmination of a lifetime of oral health issues, primarily advanced tooth decay, and severe gum disease, although it can also result from trauma or other factors. On a global scale, the average prevalence of complete tooth loss among individuals aged 20 or older is nearly 7%. However, for those aged 60 or older, the prevalence rises significantly to approximately 23%. The loss of teeth can have profound psychological, social, and functional consequences, causing emotional distress, social difficulties, and limitations in daily activities.(1) Adrian LaTrace, CEO of Boyd Industries, notes, “As innovations in dental implant technology and equipment continue to advance and doctors refine their techniques, the future holds even more remarkable breakthroughs in this field of dentistry.”

Dental implants have come a long way since their primitive predecessors, which included carved bamboo pegs, seashells, and animal teeth.(2) Modern-day dental implants replicate the look, feel, and function of natural teeth. They offer patients a permanent and durable solution, restoring oral health and enhancing overall well-being. The dental implant industry has experienced significant growth; the global dental implant market is projected to reach $13 billion in 2023.(3) Factors contributing to the industry’s progression in North America include a growing geriatric population with high incidences of dental problems, increased awareness of the importance of oral health, and a growing interest in achieving that perfect smile.(4)

Currently, 6% of the U.S. population have dental implants, which is predicted to increase to 23% by 2026.(5) Dental implants have gained immense popularity due to their numerous benefits over alternative treatments. Unlike removable dentures, dental implants provide a permanent solution by integrating with the jawbone through osseointegration, a direct, rigid connection between the implant and the bone. This integration offers stability, strength, and durability comparable to natural teeth.(6) This significantly impacts the quality of life, enabling individuals to enjoy a varied diet and engage socially without discomfort or embarrassment.

Looking toward the future, dental implant technology continues to advance at a rapid pace:

— 3D Printing: Precise customization and improved fit through 3D printing enhance patient comfort and reduce treatment time.

— Smart Biomaterial Innovations: Advanced biomaterials promote better integration of dental implants with surrounding tissues and faster healing.

— Nanotechnology: Utilizing nanotechnology enhances the surface properties of implant materials, promotes better osseointegration and more proficient bone growth, and reduces the risk of complications.(7)

— Digital Dentistry: Digital tools like intraoral scanners, CAD (computer-aided design), and CAM (computer-assisted manufacturing) enable precise planning and execution of implant procedures, leading to better aesthetic and functional outcomes.(8)

Dental implants offer an unrivaled level of functionality, allowing individuals to eat, speak, and engage in daily activities with confidence. Moreover, dental implants are a long-term solution, with an average lifespan of 10-30 years, with the potential to last a lifetime when properly cared for.(9)

While dental implants are generally safe and reliable, like any surgical procedure, they come with certain risks. It is essential to consult with a qualified dental professional before undergoing the procedure. Potential risks include infection at the implant site, damage to surrounding structures like nerves or blood vessels, tooth sensitivity, implant failure, and complications such as sinus problems or nerve damage. For people over 60, there are additional risks, such as slower healing time, compromised bone health, and the potential to affect other preexisting health conditions.(10) A proper medical assessment and plan by a skilled and experienced professional can help minimize these risks to ensure a safe and successful implantation process.

In addition to the advancements in dental implant technology, the evolution of dental equipment has also played a vital role in ensuring patient comfort during prolonged dental procedures. The duration of an implant operation differs on a case-by-case basis, depending on the type and number of implants involved. It takes about 1-2 hours to surgically insert one tooth implant. The entire process, from the initial consultation to recovery and healing time, can be 4-11 months, depending on the circumstances and the patient’s own natural healing process.(11)

Boyd is an industry leader in the design and manufacture of state-of-the-art, ergonomically-designed dental and medical operatory equipment. LaTrace observes, “Advancements in dental equipment and technology are encouraging patients to take a more proactive role in maintaining and improving their oral health and aesthetics. Dental professionals are now equipped with powerful tools that enable precise and efficient treatment and enhanced patient comfort, making lengthy dental procedures more tolerable for both doctors and patients.”

Built to last. Built for you. Built by Boyd.

About Boyd Industries

For 65 years, Boyd Industries has been the innovative market leader in the design and manufacture of dental and medical operatory equipment. Their high-quality and reliable equipment has been the choice of dental specialty practices and dental surgery offices. The rapidly expanding Ear, Nose, and Throat market now seeks its reputation for quality and innovation. Boyd equipment is specifically designed to provide maximum practice productivity while incorporating ergonomic characteristics for the doctor, staff, and patient. As an original equipment manufacturer, they use a vertically integrated approach to ensure their process meets high-quality standards. This approach allows Boyd to control each step of component fabrication and product assembly. Boyd’s products include a full line of dental exam, treatment, and surgical chairs, dental delivery systems, LED exam and surgical lighting, custom sterilization and storage cabinetry, and doctor or assistant seating. Boyd was named the Senate Small Business of the Week in November 2020 and is a ten-time winner of the Townie Choice Award for excellence in orthodontic operatory equipment. Boyd Industries is an FDA-registered manufacturer. Built to last. Built for you. Built by Boyd. http://www.boydindustries.com/.

References:

1. World Health Organization. (n.d.). Oral Health. World Health Organization. who.int/news-room/fact-sheets/detail/oral-health

2. PFDM, T. (2021, August 16). The history of Dental implants. Texas Implant & Dental Center of Amarillo. amarillodentureclinic.com/blog/2021/08/10/the-history-of-dental-implants/

3. JA;, A. H. (n.d.). The development and future of dental implants. Dental materials journal. pubmed.ncbi.nlm.nih.gov/31969548/

4. BlueWeave Consulting and Research Pvt Ltd. (2023, May 4). Dental implants market size set to touch USD 6.48 billion with the CAGR of 6.5% by 2029: BlueWeave consulting. GlobeNewswire News Room. globenewswire.com/en/news-release/2023/05/04/2661787/0/en/Dental-Implants-Market-Size-Set-to-Touch-USD-6-48-billion-With-the-CAGR-of-6-5-by-2029-BlueWeave-Consulting.html#:~:text=North%20America%20emerged%20as%20the,oral%20preventive%20and%20restorative%20treatments

5. Forbes Magazine. (2023, April 6). Dental implants: What you need to know. Forbes. forbes.com/health/body/dental-implants-guide/#:~:text=Pioneered%20about%2050%20years%20ago,set%20to%20grow%20to%2023%25

6. Parithimarkalaignan, S., & Padmanabhan, T. V. (2013, March). Osseointegration: An update. Journal of Indian Prosthodontic Society. ncbi.nlm.nih.gov/pmc/articles/PMC3602536/

7. Chen, M.-Q. (2022, April 25). Recent advances and perspective of nanotechnology-based implants for orthopedic applications. Frontiers in bioengineering and biotechnology. ncbi.nlm.nih.gov/pmc/articles/PMC9082310/

8. Alauddin, M. S., Baharuddin, A. S., & Mohd Ghazali, M. I. (2021, January 25). The modern and digital transformation of Oral Health Care: A mini review. Healthcare (Basel, Switzerland). ncbi.nlm.nih.gov/pmc/articles/PMC7912705/

9. Team. (2021, March 29). How long do dental implants last?: Periodontal Associates. Periodontal Associates Inc. periodontal.com/how-long-do-dental-implants-last/#:~:text=Dental%20Implants%20Can%20Last%20a,ability%20to%20last%20that%20long

10. Silver, N. (2022, November 21). Are dental implants safe? learn about potential risks. Healthline. healthline.com/health/dental-and-oral-health/are-dental-implants-safe#potential-risks

11. Dental, S. (2022, December 16). Just how long does dental implant treatment actually take?. Sheendental. sheendental.co.uk/post/just-how-long-does-dental-implant-treatment-actually-take

The Memorial Cardiac & Vascular Institute is a cardiovascular care leader, offering a wide array of services dedicated to the prevention, detection, and treatment of cardiovascular disease.

“Your risk of developing an arrhythmia is based largely on the type of heart defect you have and the surgery, which leaves a scar in a specific location in your heart. Based on that, we can often tell what type of arrhythmia is likely.” – Dr. Daniel Benhayon Lanes

HOLLYWOOD, Fla. (PRWEB)
June 27, 2023

Taking care of your health is always important, especially when you’re born with a heart defect (congenital heart disease). Having a heart defect makes other health problems more likely. Arrhythmia, an irregular heartbeat, is a serious concern for those with adult congenital heart disease (ACHD).

Most arrhythmias aren’t fatal, but they can cause symptoms like heart palpitations, a rapid heart rate and fatigue. The bigger problem? They double your risk of stroke and they’re the leading cause of hospitalizations for those with ACHD. Screening for and treating arrhythmias is essential for staying healthy.

CARDIAC ARRHYTHMIAS DUE TO CONGENITAL HEART DISEASE

Developing an arrhythmia when you have ACHD isn’t inevitable. But you’re much more susceptible to it than someone without a heart defect. One large study found that 15 percent of adult participants with ACHD also had atrial arrhythmias, the most common irregular heartbeat associated with the condition. More than half of those with severe ACHD developed an arrhythmia by the time they turned 65.

HOW DOES CONGENITAL HEART DISEASE CAUSE ARRHYTHMIA?

Both congenital heart disease and surgery to correct defects make you prone to arrhythmias. Here’s why: An electrical signal moves from the top to the bottom of the heart to make it contract (squeeze). That creates your heartbeat, which pushes blood out to the rest of the body.

In ACHD, arrhythmias usually occur because something interferes with the movement of the electrical impulse through the heart. The causes could include:

• Abnormal structure of the heart or surrounding blood vessels
• Prosthetic patches (synthetic material) from heart repair
• Surgical scar tissue
• Thickening of heart tissue

“Your risk of developing an arrhythmia is based largely on the type of heart defect you have and the surgery, which leaves a scar in a specific location in your heart. Based on that, we can often tell what type of arrhythmia is likely,” says Daniel Benhayon Lanes, MD, an electrophysiologist (EP) at Memorial Cardiac and Vascular Institute.

COMMON CONGENITAL ARRHYTHMIAS

ACHD is typically associated with certain types of arrhythmias, including:

• Atrial flutter: This type of arrhythmia occurs when the upper chambers of the heart (atria) contract too fast and get out of sync with the lower chambers.
• Atrial fibrillation (AFib): With AFib, the upper chambers quiver instead of contract, which causes an irregular rhythm. AFib is the most common arrhythmia in people over 65 with ACHD.
• Intra-atrial reentry tachycardia (IART): IART triggers episodes of a rapid heartbeat that stem from an unusual place in the heart’s upper chambers. This type of arrhythmia is most common in people under 50 with ACHD. IART can gradually progress to AFib.

WHAT TRIGGERS ARRHYTHMIAS?

Arrhythmias can develop immediately following surgery or occur years or decades later. Besides surgery, multiple factors can trigger arrhythmias, including:

• Excessive alcohol use
• High blood pressure
• Infections
• Weight gain

ARRHYTHMIA MANAGEMENT

Having an arrhythmia when you have ACHD is concerning because it can lead to a stroke. An irregular heartbeat may allow blood to pool in the heart and clot. When a clot breaks free, it circulates through blood vessels and can lodge in one that leads to the brain.

A stroke occurs when a clot obstructs blood flow (and oxygen) to the brain. To reduce the risk of stroke from arrhythmia, it’s essential to screen for arrhythmias and treat them.

Cardiologists use several tests and procedures to diagnose arrhythmias. Your cardiologist may recommend testing for arrhythmia if you’re having symptoms such as:

• Dizziness
• Fatigue
• Feeling like your heart is beating in your throat
• Fluttering or pounding in your chest
• Racing heart rate

Seek immediate medical attention if you experience emergency symptoms:

• Chest pain or pressure
• Fainting
• Shortness of breath

TREATMENTS

Arrhythmia treatment minimizes stroke risk and regulates your heart’s rhythm. Common treatments include:

• Blood thinners: These medications reduce your stroke risk by preventing your blood from clotting.
• Medications: Drugs that control heart rate or change the rhythm help get your heartbeat back on track.
• Electrical cardioversion: If your heart is in a constant arrhythmia, you may need this medical procedure. It delivers a small electrical shock to your heart to reset its rhythm.
• Catheter ablation: During this minimally invasive procedure, the doctor weaves a thin, hollow tube (catheter) through a blood vessel to your heart. Then they deliver heat or cold energy through the catheter to destroy the heart tissue causing the arrhythmia.

SCHEDULE AN APPOINTMENT FOR HEART AND VASCULAR SERVICES

When you have ACHD, the program and team you choose to care for your heart can make a big difference. Learn more about ACHD treatments and services at Memorial Cardiac and Vascular Institute. To schedule an appointment with a cardiologist, electrophysiologist or vascular specialist at Memorial, call 855-400-6284.

Share article on social media or email:

Vanessa Harris, PE, is a licensed civil engineer and documentary filmmaker with multiple disabilities.

“This award is a tremendous honor and it is a testament to the important work we are doing to engage the disability community,” said Harris.

CHICAGO (PRWEB)
June 27, 2023

Strategy for Access announced today that its founder and CEO, Vanessa A. Harris, PE, was named to the 2023 Leaders for a New Chicago cohort by the Field Foundation of Illinois and The John D. and Catherine T. MacArthur Foundation. The award recognizes Harris’s role as one of Chicago’s transformational leaders for her work developing films that empower and inform people with disabilities.

“This award is a tremendous honor and it is a testament to the important work we are doing to engage the disability community,” said Harris. “As someone who personally understands the problems people with disabilities face on a daily basis, I am on a mission to reach a wide and diverse audience with our stories.”

The Leaders for a New Chicago program recognizes past accomplishments and seeks to build a more inclusive city by promoting leaders who are designing new approaches to civic discourse and action. Each of the 2023 awardees will receive an award of $25,000, and their affiliated organizations will receive an additional $25,000 general operating grant. The leaders’ work aligns with the Field Foundation’s grantmaking areas of Art, Justice, and Media & Storytelling, with a focus on organizations addressing systemic issues in the city’s historically underserved communities.

“We will utilize this award to further our mission of providing educational and entertaining films for people with disabilities,” said Harris. “Our community is an integral part of society, and every individual has a significant contribution to share.”

About Strategy for Access

Strategy for Access is a for-purpose organization dedicated to producing media that benefits all people living with disabilities, primarily through its website, Fun4theDisabled. As the parent nonprofit for Fun4theDisabled’s creative work, Strategy for Access manages the legal and funding endeavors and Fun4theDisabled focuses on producing high-quality and engaging videos.

Share article on social media or email:

Prevent Blindness has declared July as Dry Eye Awareness Month to help educate the public on the eye disease, including risk factors, symptoms, and treatment options.

“Dry eye is a serious condition that may have long-term effects on eye health, if left untreated,” said Jeff Todd, president and CEO of Prevent Blindness.

CHICAGO (PRWEB)
June 27, 2023

Nearly 16 million Americans have dry eye, according to the National Eye Institute (NEI). Dry eye occurs when there is not enough tear film produced, the tear film is not draining properly from the eye, or the tear film is not the quality needed to maintain the health of the eye. If left untreated, dry eye can cause damage to the cornea.

In an effort to educate the public on dry eye, Prevent Blindness, the nation’s leading nonprofit eye health organization, has declared July as “Dry Eye Awareness Month.” Information is available on dry eye risk factors, symptoms, and treatment options through a variety of resources, including fact sheets and shareable social media graphics, available in English and Spanish, and a dedicated web page: https://preventblindness.org/understanding-dry-eye.

This year, Prevent Blindness is offering a new episode of the Focus on Eye Health Expert Series, “Dry Eye and Meibomian Gland Dysfunction (MGD),” featuring April Jasper, OD, FAAO, Advanced Eyecare Specialists. Dr. Jasper shares her unique experience as a dry eye patient as well as an eyecare provider. MGD is a condition when the eyelid glands do not produce enough oil, or it is of poor quality.

For the third consecutive year, OCuSOFT ® Inc., a privately-held eye and skin care company dedicated to innovation in eyelid hygiene and ocular health, is partnering with Prevent Blindness in support of Dry Eye Awareness Month.

Risk factors for dry eye include:

• Being more than 50 years old
• Hormonal changes
• Refractive surgery (for example, Lasik)
• Inflammation of the eyelids
• Environmental conditions, such as allergies, exposure to smoke, or a dry climate
• Prolonged use of digital screens, such as computers
• Wearing contact lenses
• Medical conditions such as diabetes, thyroid eye disease, rheumatoid arthritis, lupus, Sjogren’s syndrome, and certain other autoimmune diseases

Additionally, taking certain medicines increases the risk of dry eye. According to the American Academy of Ophthalmology, these include diuretics (water pills) for high blood pressure, beta-blockers, for heart problems or high blood pressure, allergy and cold medicines (antihistamines), sleeping pills, anxiety and antidepressant medicines, and heartburn medicines. Patients must inform their eyecare professional of all medications they are taking in order to treat dry eye and other eye conditions effectively.

“Dry eye is a serious condition that may have long-term effects on eye health, if left untreated,” said Jeff Todd, president and CEO of Prevent Blindness. “We encourage patients to talk with their eye doctors about their dry eye symptoms, and work together to form an effective treatment plan to keep eyes healthy for years to come.”

For more information on dry eye, please visit the Prevent Blindness resource page at PreventBlindness.org/understanding-dry-eye.

About Prevent Blindness

Founded in 1908, Prevent Blindness is the nation’s leading volunteer eye health and safety organization dedicated to fighting blindness and saving sight. Focused on promoting a continuum of vision care, Prevent Blindness touches the lives of millions of people each year through public and professional education, advocacy, certified vision screening and training, community and patient service programs and research. These services are made possible through the generous support of the American public. Together with a network of affiliates, Prevent Blindness is committed to eliminating preventable blindness in America. For more information, visit us at PreventBlindness.org, and follow us on Facebook, Twitter, Instagram, LinkedIn and YouTube.

###

Share article on social media or email:

Collecting, tracking, and analyzing data in real-time generates immediately actionable insights and helps to identify opportunities, reduce risk, and make better decisions

TYSONS CORNER, Va. (PRWEB)
June 27, 2023

As of June 2023, there are 455,756 active clinical trials in all 50 U.S. states and 221 countries worldwide.(1) Unfortunately, studies indicate that the overall success rate of clinical trials is only 7.9%, meaning that, statistically speaking, over 90% of those trials will be unsuccessful.(2) Dr. Harsha Rajasimha, Founder and CEO of Jeeva Informatics, explains, “The exceedingly high failure rate of clinical trials is not necessarily due to the lack of efficacy of the treatment being studied, but it’s often the lack of efficacy of the study itself.” It appears that the FDA is aligned with this view, given its recent guidance for the industry that encourages it to further modernize its approach to clinical trials to help boost outcomes and lower costs.

One trend in the clinical trial space that is helping to tackle the problem is the evolution of Hybrid and Decentralized Clinical Trials. The FDA has recognized the significant advantages of DCTs and is looking towards broader adoption after their successful implementation during the COVID-19 pandemic. The FDA cites the following benefits of DCTs:

• Improving convenience for clinical trial participants.
• Alleviating the burden on caregivers.
• Expanding access to more diverse populations.
• Improving trial efficiencies.
• Facilitating research on rare diseases.
• Enabling broader participation for populations with limited mobility.(3)

To these ends, the FDA has recently introduced new guidance to support DCTs in researching the efficacy of investigational drugs, biologics, and medical devices. The new guidance provides recommendations to address the unique challenges for DCTs. There needs to be coordination of all trial activities across multiple locations to address the prevalent issues of design, feasibility, implementation, and analytical considerations to facilitate the decentralization of the trial.

To make clinical trials more accessible, the FDA recommends convenience strategies for participants, such as telehealth visits when physical interaction is not necessary, employing local healthcare personnel (HCP) to perform in-person assessments, and providing HCPs with comprehensive training in following research protocols regarding the proper administration of investigational products (IPs).(4)

To manage DCT operations, the FDA suggests using software that is versatile and can be utilized on various platforms such as tablets, cell phones, and personal computers; it should also be able to handle multiple investigative functions, including:

• Managing electronic informed consent.
• Capturing and storing reports from remote trial personnel, local HCPs, and remote clinical laboratory facilities.
• Managing electronic case report forms (eCRFs).
• Scheduling trial visits and other DCT-related activities.
• Tracking IPs that are shipped directly to trial participants.
• Syncing information recorded by digital health technologies (DHTs).
• Serving as communication tools between DCT personnel and trial participants.(4)

Rajasimha notes, “Collecting, tracking, and analyzing data in real-time generates immediately actionable insights and helps to identify opportunities, reduce risk, and make better decisions. With the FDA’s continued support and guidance, decentralized and hybrid clinical trials can continue to gain momentum and cement their role in the future of clinical research.”

Pharma companies typically spend over $60 million on a large clinical trial.(5) If regulatory bodies deem the gathered data invalid, the loss could devastate the clinical trial and possibly the company altogether. Because the FDA holds biopharmaceutical companies responsible for regulatory compliance via audits, these companies need to make sure they are in compliance at all times with a system that not only complies with regulatory and security requirements but also provides human-centric and flexible real-time monitoring of sites, patients, and their data.

By using platforms that check all regulatory, security, and patient care boxes, like Jeeva™ eClinical Cloud, biopharmaceutical companies can be fully compliant from the start, saving money, time, and effort.

A human-centric, secure, unified, and flexible platform that is designed specifically for decentralized and hybrid trials and adheres to FDA guidelines and recommendations can accelerate clinical research timelines over 3x faster. This is what Rajasimha and his team have worked tirelessly to deliver to their sponsors and CRO customers since the start of the COVID pandemic.

About Jeeva Informatics

The personal experience of losing a child born with a rare congenital disorder and a brother with a chronic disease became the springboard for Dr. Harsha Rajasimha to apply his years of postdoctoral training at the NIH and FDA to accelerate therapies for rare and common conditions. Patient travel requirements and the pandemic forced the demand for decentralizing clinical trials and embracing digital technologies needed to accelerate the process of bringing new medicines or vaccines to patients who need them over three times faster. Jeeva set out to focus on mitigating risks to emerging biopharma clinical trial sponsors as true technology partners, seeking time and cost-efficient ways to execute early-stage clinical trials with minimal risk without compromise. Their reduction of the logistical burdens on patients and study teams by over 70% has resulted in their eClinical platform being selected by a joint venture of Georgetown University Medical Center and Frantz Medical Group for a major cancer trial. The Virginia-based company’s modular software-as-a-service platform is fully scalable and facilitates patient enrollment, engagement, and evidence generation in clinical trials on any browser-enabled mobile device. Visit https://jeevatrials.com/.

References

1. Trends, charts, and maps. ClinicalTrials.gov. (n.d.). clinicaltrials.gov/ct2/resources/trends.

2. Kim, E., Yang, J., Park, S.; Shin, K. (2023, May 11). Factors affecting success of New Drug Clinical Trials. Therapeutic innovation; regulatory science. ncbi.nlm.nih.gov/pmc/articles/PMC10173933/.

3. Commissioner, O. of the. (n.d.). FDA takes additional steps to advance decentralized clinical trials. U.S. Food and Drug Administration. fda.gov/news-events/press-announcements/fda-takes-additional-steps-advance-decentralized-clinical-trials#:~:text=%E2%80%9CThe%20FDA%20has%20long%20considered,said%20FDA%20Commissioner%20Robert%20M.

4. Decentralized clinical trials for drugs, biological products, and … (n.d.-a). fda.gov/media/167696/download.

5. Clinicubes. (2022, September 12). Many stakeholders + different costs = complex clinical trial (part 1). Clinicubes. clinicubes.com/many-stakeholders-different-costs-complex-clinical-trial-part-1/

Share article on social media or email:

G-CON PODs ready for installation at Just-Evotec in Toulouse, France

The combination of the PODs and cleanroom panels from G-CON Clean Solutions were seamlessly integrated by our teams for Just-Evotec Biologics, our first hybrid customer in Europe.

COLLEGE STATION, Texas (PRWEB)
June 27, 2023

G-CON, the global leader in off-site prefabricated cleanroom systems, recently celebrated the arrival and start of the installation of PODs at Evotec’s Campus Curie in Toulouse, France. The Toulouse project is the first hybrid project for G-CON, delivering both PODs and G-CON Clean Solutions architectural systems. G-CON previously supplied the cleanroom PODs for the first J.POD facility at Just – Evotec Biologics’ site in Redmond, WA (US) in August 2021 where they have been performing process development and GMP clinical manufacturing for partners such as the U.S. Department of Defense.

“The combination of the PODs and cleanroom panels from G-CON Clean Solutions were seamlessly integrated by our teams for Just-Evotec Biologics, our first hybrid customer in Europe,” said Dr. Anne Jones, President and CEO of G-CON. “We are thrilled to partner with Just Evotec Biologics, where our combined products are integral to supporting the build out of their leading-edge manufacturing platform.”

Dr. Linda Zuckerman, Executive Vice President, Global Head Biotherapeutics at Just – Evotec Biologics, commented, “The installation of multiple cleanroom PODs by the G-CON team advances the construction of J.POD Toulouse, France (EU) significantly. The PODs are one of the cornerstones for our continuous manufacturing platform enabling advanced and efficient biomanufacturing processes available to our partners for the benefit of patients worldwide.”

About G-CON

G-CON specializes in the design and construction of advanced cleanroom solutions for a wide range of industries. G-CON works closely with customers and A&Es to provide solutions that meet their specific needs, building PODular cleanrooms offsite, and providing modular and hybrid construction options. These offerings enable rapid deployment and easy configuration of cleanrooms while delivering the highest quality facilities, quickly and on time and on budget as well. For more information visit http://www.gconbio.com.

About JUST – EVOTEC BIOLOGICS

Just – Evotec Biologics, wholly owned by Evotec SE, is a first-to-industry biologics platform company that leverages AI/ML technologies and world-leading molecular design, cell line development, process intensification and continuous manufacturing strategies to advance biotherapeutics from discovery through clinical stages to commercial launch. The Just – Evotec Biologics team combines deep industry experience in the fields of data, protein, process, and manufacturing sciences including automation with highly integrated and flexible capabilities to break through the scientific and economic barriers associated with the development of protein therapeutics. Our focus is to accelerate and expand access to biotherapeutics through scientific and technological innovation for our proprietary projects and on behalf of our partners. Learn more at http://www.just-evotecbiologics.com.

For more information contact:

Brittany Berryman

Director of Marketing

G-CON Manufacturing, Inc.

6161 Imperial Loop, College Station, TX 77845

Phone: 979-431-0700

e-mail: bberryman@gconbio.com

http://www.gconbio.com

Share article on social media or email:

A-Alpha Bio

Her extensive experience as a biotechnology leader, founder, and operator will be instrumental in successfully developing our platforms, progressing our pipeline, and advancing A-Alpha Bio’s mission to improve human health by measuring and engineering protein-protein interactions.

SEATTLE (PRWEB)
June 27, 2023

A-Alpha Bio, a synthetic biology and machine learning company that measures and engineers protein-protein interactions, announced the appointment of Heidi Hagen to their Board of Directors. Hagen will be A-Alpha Bio’s first independent board member.

Hagen has been a leader in the Biotechnology industry for 30 years. Over the course of her career, she has built an extensive track record in leading strategy and operations to progress innovative technologies from ideation to commercialization. Having been a core member of pharma companies like Vineti, Sotio, and Dendreon, Hagen intimately understands how pharma and biotech companies operate and scale from startup to global organization. Her experiences as a founder, C-Suite executive, and key operator in the growth and exits of numerous companies provide A-Alpha Bio with a wealth of valuable insights and lessons learned.

“We are thrilled to welcome Heidi to our Board of Directors,” said David Younger, CEO and Co-Founder of A-Alpha Bio. “Her extensive experience as a biotechnology leader, founder, and operator will be instrumental in successfully developing our platforms, progressing our pipeline, and advancing A-Alpha Bio’s mission to improve human health by measuring and engineering protein-protein interactions.”

Hagen has remained at the forefront of biotech innovation and business leadership with expertise spanning technical areas from protein therapeutics to cell therapies. Based in Seattle, Hagen will be on the ground to support and share her expertise and network with the A-Alpha Bio team.

“I am excited to join A-Alpha Bio’s Board of Directors and collaborate with this dynamic team of biologists, protein engineers, and data scientists,” said Hagen. “I believe that the convergence of machine learning and synthetic biology holds immense potential for advancing the development of novel therapeutics, particularly in the area of protein-protein interactions. Drawing from my diverse experiences in biotechnology, I am eager to work alongside A-Alpha Bio to achieve their goals and significantly impact human health.”

Hagen most recently served as Chief Technology Officer at Sonoma Biotherapeutics, an immune tolerance company engineering regulatory T cell (Treg) therapies to treat autoimmune and inflammatory diseases. Prior to that, she focused on precision medicine through her roles as the Co-Founder and former Chief Strategy Officer at Vineti, the Global Chief Operating Officer at Sotio, the Senior Vice President of Operations at Dendreon Corporation, and the Senior Manager of Supply Operations at Immunex Inc. In addition, Hagen serves as a board member and Governance Committee Chair for Obsidian Therapeutics and Vericel Corporation (NASDAQ:VCEL). Previously, Hagen also served on the boards of Alaunos Therapeutics and Lykan Biosciences.

Hagen earned her B.S. in cell and molecular biology, her M.S. in bioengineering, and her M.B.A all from the University of Washington, where her studies focused on the interaction between science and business.

For more information on A-Alpha Bio, please visit: https://www.aalphabio.com/.

About A-Alpha Bio

A-Alpha Bio uses synthetic biology and machine learning to measure, discover, predict, and engineer protein-protein interactions.

The company’s AlphaSeq platform applies synthetic biology to experimentally measure millions of protein-protein interaction affinities simultaneously. Protein binding data is incorporated into the company’s AlphaBind platform to train machine learning models that predict binding from sequence. A-Alpha Bio uses both platforms to discover and optimize high-impact therapeutics for their own pipeline and in partnership with industry leaders.

A-Alpha Bio is based in Seattle and was founded in 2017 at the University of Washington’s Institute for Protein Design and Center for Synthetic Biology. To learn more, please visit: https://www.aalphabio.com/.

Share article on social media or email:

Benchmark Senior Living “Welcome Home” Campaign

“Our communities aren’t just a place for older adults to live, they’re a place where everyone is connected and invested in seeing one another happy and engaged in what they enjoy.” -Tom Grape, founder, chairman and CEO of Benchmark

WALTHAM, Mass. (PRWEB)
June 27, 2023

Today, Benchmark Senior Living, New England’s largest senior living provider with 65 independent living, assisted living, memory care assisted living and continuing care retirement communities throughout the Northeast, announced the debut of a new advertising campaign. The campaign, entitled Welcome Home, is designed to highlight the many ways in which Benchmark communities exceed expectations and enhance quality of life so that residents and their family members truly feel at home.

The multimedia campaign utilizes creative storytelling and impactful visuals to showcase the deep relationships formed within Benchmark communities and the special moments regularly shared between residents themselves and the passionate team that supports them. For example, the opportunity to begin one’s day with morning walks, enjoy chef-prepared meals, learn something new and end the day with concerts and dancing with people who care. Also, enjoy the little things that make life special like associates who truly know you.

“Our communities aren’t just a place for older adults to live, they’re a place where everyone is connected and invested in seeing one another happy and engaged in what they enjoy,” said Tom Grape, founder, chairman and CEO of Benchmark. “This campaign brings to life the true sense of home that Benchmark has provided to our residents, their families and our associates for more than 26 years.”

The outstanding care and experiences offered at Benchmark communities are made possible thanks to dedicated associates who are hired for heart and trained for skill. Associates are committed to fostering independence and nurturing residents’ passions and connections with care and personalized programs that keep them connected to who and what matters most in their lives.

Welcome Home launched today in major newspapers, online and social media.

The campaign was developed by Benchmark’s new creative agency of record, Boston-based Colossus. “A big reason we started Colossus was to choose our clients. Supporting Benchmark employees, who do incredible work that improves lives, fits our own values and we’re proud to be their partner,” said Colossus Managing Director, Jon Balck.

Colossus is an advertising and creative company partnering with like-minded brands who view creativity as a business lever. Their goal is to help brands break through the white noise of the mundane by shaping art, technology and commerce into meaningful experiences.

Benchmark senior assisted living communities offering independent assisted living and assisted living with memory care are located throughout Connecticut, Massachusetts, New Hampshire, Rhode Island, New York, Maine and Vermont. Benchmark Senior Living is also a respite care provider. Click here to learn more.

About Benchmark Senior Living

Benchmark is New England’s largest senior living provider with 65 independent living, assisted living, memory care and continuing care communities and over 5,000 dedicated associates providing compassionate care and outstanding experiences throughout the Northeast. The Waltham, Mass.-based company was founded over 25 years ago by Tom Grape with the purpose of Transforming Lives Through Human Connection. Since then, Benchmark has continued to set the industry standard, having won over a hundred local, regional and national awards for its care, programs and as a top workplace. Benchmark has been named one of the Top Places to Work for 15 straight years in The Boston Globe’s annual employee-based survey and received repeated recognition in FORTUNE’s Best Workplaces for Aging Services list. For more information, visit BenchmarkSeniorLiving.com.

Share article on social media or email: